XTalks

FEBRUARY 8, 2024

Diabetes remains a critical global challenge, affecting millions of lives and commanding significant attention from the medical, life sciences and pharmaceutical sectors. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5 billion in Q4 2022.

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

MARCH 1, 2021

Anti-inflammatory drugs like Restasis and Xiidra are popular treatment options for the condition, but will the emergence of mask-associated dry eye bolster their sales? But if you thought the growing number of patients presenting with mask-associated dry eye would mean higher sales for Restasis, think again.

Sales 119

Sales Drugs Life Science Containment 119

XTalks

NOVEMBER 9, 2023

Since its approval in May 2022, Mounjaro sales have hit $1.4 In the first half of 2023, sales of Ozempic and Wegovy rose by 58 percent and 363 percent, respectively. Zepbound contains mimetics of the GLP-1 and GIP hormones that regulate appetite and blood sugar. billion in just one year and a quarter. billion for Novo.

FDA Approval 59

FDA Approval Manufacturing Drugs Pharmacy 59

XTalks

MARCH 15, 2023

Strattera’s active ingredient is the SNRI atomoxetine hydrochloride while Qelbree contains viloxazine hydrochloride, a serotonin-norepinephrine modulating agent (also a SNRI). Norepinephrine is a hormone and neurotransmitter that helps in alertness and maintaining control in high-stress situations. million, which was down from $854.7

Drugs 98

Drugs Sales Trials Marketing 98

XTalks

NOVEMBER 9, 2022

Since Mounjaro’s May US Food and Drug Administration (FDA) approval, sales of the drug have skyrocketed beyond initial expectations owing to patient demand and a temporary shortage of Novo’s Ozempic. GIP is a metabolic hormone that promotes insulin secretion and also weakly inhibits gastric acid secretion to suppress appetite.

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

AUGUST 2, 2023

Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. It contains the antiviral medications nirmatrelvir and ritonavir. It is a CDK 4/6 inhibitor that is taken in combination with other hormonal therapies to stop the growth of cancer and healthy cells. billion in 2022, a 23.43

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

MARCH 11, 2021

The company is taking steps aimed at strengthening sales growth, profitability and free cash flow. We plan to continue to grow at Pharmaceuticals despite patent expirations and only expect to register a modest decline in sales in 2024,” he said. Speeding up sales growth. through 2023.

Sales 52

Sales Gene Therapy Marketing Gene 52